therapeut
vaccin
lymphoma
patient
tumorspecif
immunoglobulin
idiotyp
id
coupl
carrier
protein
keyhol
limpet
hemocyanin
idklh
undergo
clinic
investig
method
improv
immunogen
protein
tumor
antigen
vaccin
sought
id
protein
produc
via
tumormyeloma
hybridoma
recombin
method
mammalian
bacteria
insect
cell
demonstr
termin
mannos
residu
characterist
recombin
protein
produc
insect
cell
yield
id
protein
significantli
enhanc
immunostimulatori
properti
compar
id
protein
deriv
mammalian
cell
recombin
baculovirusinfect
insect
cellderiv
id
show
higher
bind
activ
human
dendrit
cell
mediat
mannos
receptor
vivo
insect
cellderiv
id
elicit
higher
level
tumorspecif
ctl
improv
erad
preestablish
murin
lymphoma
insect
cell
mammalian
id
gener
similar
level
tumorspecif
antibodi
show
impair
antibodi
respons
nativ
tumor
antigen
despit
glycoslyl
differ
immunogen
combin
insect
cell
product
maleimidebas
klh
conjug
offer
highest
level
antitumor
immun
data
compar
sourc
recombin
id
protein
tumor
antigen
use
therapeut
cancer
vaccin
demonstr
insect
cellderiv
antigen
offer
sever
immunolog
advantag
protein
deriv
mammalian
sourc
tumorspecif
immunoglobulin
idiotyp
id
clonal
express
b
cell
lymphoma
serv
target
therapeut
vaccin
b
cell
malign
immun
fulllength
protein
tumor
antigen
goal
elicit
tumorspecif
cell
andor
antibodi
respons
capabl
inhibit
tumor
growth
tumorspecif
id
protein
isol
individu
b
cell
lymphoma
either
fusion
myeloma
cell
line
gener
tumormyeloma
hybridoma
secret
tumorspecif
ig
molecular
clone
tumor
heavyand
lightchain
variabl
region
ig
gene
product
recombin
id
varieti
express
system
method
yield
patientspecif
tumor
antigen
immun
vaccin
tumorderiv
id
may
elicit
polyclon
antibodi
respons
well
cell
recogn
idderiv
peptid
present
class
class
ii
mhc
protein
tumor
cell
surfac
improv
immunogen
id
chemic
conjug
highli
immunogen
foreign
carrier
protein
keyhol
limpet
hemocyanin
klh
phase
iii
trial
idklh
vaccin
lymphoma
patient
demonstr
correl
induc
antiid
immun
respons
improv
progressionfre
overal
surviv
clearanc
circul
lymphoma
cell
durabl
tumor
regress
prompt
initi
sever
phase
iii
clinic
trial
idklh
vaccin
achiev
optim
immun
protein
tumor
antigen
deliv
highli
immunogen
form
prefer
one
allow
effici
uptak
process
antigen
present
cell
includ
dendrit
cell
dc
antigen
process
facilit
target
antigen
scaveng
receptor
mannos
receptor
mr
bind
pathogenassoci
carbohydr
structur
rich
termin
mannos
residu
mrmediat
uptak
glycoprotein
antigen
dc
shown
enhanc
antigen
present
cell
murin
human
system
inde
mr
express
dc
appear
critic
uptak
crosspresent
solubl
glycoprotein
cell
baculoviru
express
insect
cell
repres
robust
method
produc
recombin
glycoprotein
product
recombin
protein
insect
cell
lead
alter
glycosyl
pattern
includ
rel
abund
termin
mannos
residu
therebi
offer
improv
bind
mr
present
antigen
present
cell
baculovirusproduc
protein
current
studi
vaccin
number
viral
pathogen
includ
human
papilloma
viru
influenza
hiv
hepat
e
sarscoronaviru
among
other
well
varieti
therapeut
human
cancer
vaccin
effici
larg
quantiti
recombin
protein
gener
use
baculovirusinsect
cell
system
led
adopt
approach
product
individu
lymphomaspecif
id
protein
human
clinic
trial
howev
whether
recombin
tumorspecif
id
protein
secret
insect
cell
possess
desir
immunolog
properti
mammalian
sourc
remain
unknown
thu
sought
directli
compar
immunolog
characterist
mammalian
cell
hybridoma
deriv
id
recombin
id
produc
baculovirusinfect
insect
cell
found
termin
mannos
residu
content
insect
cellderiv
protein
endow
markedli
improv
bind
human
dc
via
mr
accompani
upregul
sever
dc
activ
marker
vivo
immun
insect
cellderiv
id
induc
higher
level
cytotox
lymphocyt
ctl
activ
murin
b
cell
lymphoma
compar
hybridomaderiv
id
associ
improv
frequenc
tumor
erad
importantli
alter
glycosyl
pattern
insect
cellderiv
id
impair
abil
induc
idspecif
antibodi
reactiv
nativ
protein
approach
combin
use
recombin
insect
cellderiv
id
conjug
klh
use
recentlydescrib
maleimid
sulfhydrylbas
method
produc
highest
level
tumor
erad
tumorspecif
antibodi
data
support
use
insect
cellderiv
tumor
antigen
maleimid
conjug
clinic
trial
tumor
antigencarri
protein
conjug
vaccin
igg
purifi
human
serum
obtain
sigmaaldrich
st
loui
mo
balbc
b
cell
lymphoma
line
obtain
american
type
cultur
collect
atcc
manassa
va
cultur
previous
describ
murin
id
protein
affinitypurifi
protein
cultur
media
tumormyeloma
cell
hybridoma
hyb
id
clone
deriv
fusion
lymphoma
cell
myeloma
cell
previous
describ
recombin
baculovirusderiv
id
bv
id
produc
clone
lymphomaderiv
variabl
heavyand
lightchain
ig
cdna
sequenc
dual
express
baculoviru
plasmid
vector
follow
approxim
kb
insect
cell
express
plasmid
construct
contain
two
cassett
express
immunoglobulin
protein
contain
murin
kappa
light
chain
heavi
chain
express
first
cassett
control
baculoviru
polyhedrin
promot
polyadenyl
site
direct
synthesi
protein
contain
kappa
variabl
region
fuse
murin
kappa
light
chain
constant
region
present
ptrabac
backbon
vector
human
alkalin
phosphatas
secretori
sequenc
code
region
incorpor
backbon
vector
upstream
kappa
variabl
region
clone
site
insur
appropri
process
matur
full
length
kappa
light
chain
express
second
cassett
transcrib
opposit
strand
light
chain
express
control
baculoviru
promot
bovin
growth
hormon
polyadenyl
site
direct
synthesi
protein
contain
heavi
chain
variabl
region
fuse
murin
heavi
chain
constant
region
also
present
ptrabac
backbon
vector
honeybe
melittin
secretori
sequenc
code
region
incorpor
backbon
vector
upstream
heavi
chain
variabl
region
clone
site
insur
appropri
process
matur
full
length
heavi
chain
approxim
kb
side
code
region
promot
homolog
recombin
baculoviru
genom
transfer
vector
cotransfect
baculoviru
genom
dna
baculogold
bd
bioscienc
san
jose
ca
insect
cell
invitrogen
use
standard
lipid
base
transfect
method
insect
genejuic
emd
chemic
inc
gibbstown
nj
obtain
high
titer
baculoviru
stock
stock
use
infect
highfiv
insect
cell
trichoplusia
ni
invitrogen
carlsbad
ca
recombin
ig
product
insect
cell
line
maintain
anim
free
esfaf
insect
cell
media
express
system
woodland
ca
three
day
post
infect
fulllength
ig
purifi
clarifi
cultur
supernat
protein
affin
chromatographi
follow
ion
exchang
size
exclus
chromatographi
nucleotid
sequenc
tumor
hybridoma
recombin
heavyand
lightchain
variabl
region
ig
run
abi
appli
biosystem
foster
citi
ca
instrument
analyz
use
sequench
softwar
genecod
inc
ann
arbor
mi
variabl
region
id
sequenc
ident
modif
made
lightchain
constant
region
posit
amino
acid
chang
thr
ser
facilit
clone
kappa
chain
baculoviru
vector
tumorspecif
human
recombin
clone
follicular
lymphoma
also
produc
insect
cell
analyz
carbohydr
composit
purifi
id
protein
purifi
id
incub
hour
unitsml
pngase
f
new
england
biolab
ipswich
pngase
f
digest
buffer
mm
sodium
phosphat
ph
contain
mm
edta
sodium
azid
digest
maltopentos
intern
standard
ad
deglycosyl
antibodi
sampl
heat
minut
preci
pitat
protein
sampl
centrifug
minut
supernat
contain
oligosaccharid
dri
centrifug
vacuum
evapor
oligosaccharid
pellet
dissolv
fluoresc
dye
apt
invitrogen
reconstitut
acet
acid
sodium
cyanoborohydrid
tetrahydrofuran
label
solut
incub
hour
dilut
water
sampl
analyz
capillari
electrophoresi
beckman
coulter
proteom
lab
ce
instrument
beckman
coulter
fullerton
ca
data
collect
process
use
gold
softwar
suppli
manufactur
commerci
avail
oligosaccharid
standard
analyz
similar
fashion
migrat
time
compar
oligosaccharid
peak
observ
ig
sampl
klh
obtain
form
pierc
pierc
rockford
il
glutaraldehyd
conjug
perform
room
temperatur
use
w
w
mixtur
id
klh
glutaraldehyd
sigmaaldrich
previous
describ
maleimid
conjug
perform
previous
describ
briefli
id
protein
partial
reduc
mm
dtt
sigmaaldrich
dialyz
pb
contain
edta
prevent
reoxid
sulfhydryl
group
conjug
maleimideactiv
klh
pierc
ratio
id
klh
w
w
mgml
hour
room
temperatur
follow
dialysi
pb
plasticadher
peripher
blood
mononuclear
cell
cultur
rpmi
media
invitrogen
human
ab
serum
valley
biomed
inc
winchest
va
ngml
recombin
human
r
system
minneapoli
mn
ngml
gmcsf
berlex
montvil
new
jersey
cytokin
media
chang
everi
day
day
nonand
looselyadher
cell
harvest
klh
human
iggklh
bviggklh
conjug
label
fitc
use
fluoreport
fitc
protein
label
kit
invitrogen
fitcprotein
ratio
approxim
conjug
immatur
monocytederiv
human
dc
incub
fitcconjug
human
igg
klh
bvderiv
human
igg
antibodi
presenc
normal
human
ab
serum
minut
cell
wash
twice
stain
buffer
analyz
flow
cytometri
cell
cultur
without
fitcconjug
protein
serv
neg
control
murin
id
protein
bvor
hybderiv
label
alexa
fluor
protein
label
kit
invitrogen
ml
fitcdextran
sigmaaldrich
incub
human
dc
hour
rpmi
fc
mix
pb
cell
wash
icecold
fac
buffer
fix
paraformaldehyd
flow
cytometr
analysi
use
bd
facscalibur
flow
cytomet
bd
bioscienc
fc
express
analysi
softwar
de
novo
softwar
lo
angel
ca
aliquot
cell
also
pretreat
variou
block
agent
minut
addit
id
antigen
evalu
effect
bind
mr
cell
surfac
block
agent
includ
mgml
mannan
sigmaaldrich
antimr
antibodi
clone
bd
bioscienc
control
igg
mous
biogenidec
san
diego
ca
cytochalasin
sigmaaldrich
immatur
human
dc
incub
hour
rpmi
media
plu
human
ab
serum
bvor
hybderiv
id
conjug
klh
via
glutaraldehyd
sampl
antimr
antibodi
ad
start
cultur
cell
harvest
stain
fitclabel
antihuman
pelabel
antihuman
tclabel
antihuman
apclabel
antihuman
monoclon
antibodi
bd
bioscienc
analyz
flow
cytometri
balbc
mice
bred
hous
radiat
oncolog
barrier
facil
defin
pathogen
coloni
ucla
lo
angel
ca
experi
conduct
accord
ucla
anim
care
guidelin
group
balbc
mice
week
age
inocul
subcutan
sc
cell
day
begin
day
mice
given
either
weekli
vaccin
bvor
hybderiv
idklh
conjug
use
either
glutaraldehyd
maleimid
chemistri
vaccin
includ
consecut
day
ng
gmcsf
bd
bioscienc
given
locat
mice
sacrif
tumor
reach
cm
diamet
per
institut
protocol
cell
deplet
studi
anim
inject
intraperiton
ip
antibodi
bioxcel
west
lebanon
nh
control
rat
igg
sigmaaldrich
st
loui
mo
day
weekli
thereaft
deplet
confirm
day
flow
cytometri
mice
given
biweekli
vaccin
bvor
hybderiv
glutaraldehyd
idklh
plu
gmcsf
fourteen
day
later
postvaccin
spleen
lymph
node
harvest
pool
individu
mice
process
singl
cell
suspens
cell
cultur
day
mitomycin
c
sigmaaldrich
treat
tumor
cell
end
cultur
viabl
cell
purifi
via
centrifug
histopaqu
sigmaaldrich
live
cell
count
phenotyp
enumer
total
cell
flow
cytometri
recov
cell
coincub
invitrogen
cell
ml
fc
rpmi
media
hour
follow
incub
pi
sigmaaldrich
ad
sampl
cell
assess
immedi
flow
cytometri
percent
lysi
calcul
pi
target
cellstot
target
evalu
antibodi
respons
gener
bvor
hybderiv
idklh
vaccin
group
balbc
mice
receiv
weekli
vaccin
mice
bled
day
third
vaccin
antiid
antibodi
measur
previous
describ
f
ab
hybridoma
id
coat
onto
nunc
immunosorp
nalg
nunc
rochest
ny
plate
carbon
buffer
overnight
plate
block
nonfat
dri
milk
wash
sera
serial
dilut
along
antiid
standard
mous
kind
gift
dr
ronald
levi
stanford
ca
hour
room
temperatur
plate
wash
incub
goat
antimous
igghrp
secondari
detector
antibodi
specif
southern
biotech
birmingham
al
wash
develop
abt
sigmaaldrich
surviv
differ
among
group
mice
assess
use
kaplanmei
method
logrank
test
use
prism
softwar
graphpad
softwar
san
diego
ca
p
valu
consid
statist
signific
p
less
express
ctl
antibodi
titer
data
compar
use
pair
student
test
differ
consid
statist
signific
p
less
cdna
sequenc
lymphoma
heavyand
lightchain
ig
variabl
idiotyp
region
clone
baculoviru
vector
express
murin
backbon
match
nativ
id
produc
highfiv
insect
cell
variabl
region
cdna
bvand
hybderiv
id
sequenc
confirm
ident
data
shown
compar
carbohydr
analysi
bvand
hybderiv
id
protein
capillari
electrophoresi
demonstr
typic
nlink
glycosyl
pattern
mammalianderiv
ig
characterist
oligomannosid
nglycan
five
nine
mannos
residu
insect
cellderiv
protein
fig
pattern
repres
human
lymphomaderiv
bv
id
protein
produc
idklh
vaccin
clinic
trial
data
shown
given
high
content
termin
mannos
residu
bvderiv
id
hypothes
bind
uptak
bv
id
dc
may
differ
nativ
tumorderiv
id
fitclabel
human
igg
bvderiv
human
igg
conjug
klh
via
glutaraldehyd
incub
immatur
human
dc
depict
fig
klh
alon
human
iggklh
show
modest
roughli
equival
degre
bind
dc
contrast
bvderiv
human
iggklh
conjug
demonstr
substanti
higher
fold
increas
mean
fluoresc
intens
mfi
stain
human
dc
similarli
incub
dc
allow
bind
uptak
protein
fluoresc
alexa
hyb
id
free
alexa
show
moder
uptak
human
dc
bvderiv
id
display
strikingli
higher
uptak
fold
increas
mfi
fig
sinc
amino
acid
sequenc
two
id
protein
essenti
ident
differ
substanti
glycan
content
sought
determin
role
mr
affin
protein
dc
human
dc
incub
fluorescentlabel
bv
id
hyb
id
dextran
presenc
variou
endocytosi
inhibitor
fig
highlevel
bind
uptak
bv
id
dextran
synthet
ligand
mr
dc
partial
block
presenc
mannosecontain
polysaccharid
mannan
block
antibodi
mr
affect
control
antibodi
contrast
inhibitor
affect
bind
uptak
hyb
id
cytochalasin
inhibitor
microfilamentdepend
endocytosi
reduc
dc
uptak
bv
id
hyb
id
dextran
expect
result
demonstr
role
dc
mr
increas
uptak
bvderiv
antigen
compar
mammalian
cellderiv
counterpart
interestingli
despit
fact
klh
contain
mannos
residu
bind
mannos
receptor
glycan
content
bvderiv
id
permit
even
higher
bind
dc
mannos
receptor
ligat
ctype
lectinlik
scaveng
receptor
mr
dc
contribut
activ
surfac
express
two
repres
dc
activ
marker
evalu
incub
bv
hyb
glutaraldehyd
idklh
conjug
immatur
human
dc
five
donor
evalu
surfac
express
fig
fig
hour
cocultur
dc
incub
bv
idklh
conjug
show
significantli
higher
level
express
compar
dc
incub
hyb
idklh
dc
expos
unconjug
klh
show
surfac
marker
level
roughli
equival
seen
media
alon
control
data
shown
increas
express
dc
cultur
hyb
idklh
versu
media
alon
may
account
part
mannos
content
klh
addit
block
antimr
antibodi
cocultur
reduc
higher
level
surfac
marker
express
seen
bv
id
mani
case
near
level
seen
hyb
id
protein
fig
moreov
marker
express
presenc
hyb
id
protein
greatli
affect
antimr
antibodi
thu
enhanc
bind
uptak
bv
id
dc
associ
induct
matur
immunophenotyp
appear
mediat
part
interact
mr
set
bvand
hybderiv
id
protein
permit
us
assess
impact
insect
cell
id
product
lymphomaspecif
immun
vivo
mice
bear
earli
establish
sc
tumor
vaccin
bv
hyb
id
conjug
klh
via
either
glutaraldehyd
maleimid
chemistri
standard
id
vaccin
clinic
trial
hyb
id
conjug
klh
via
glutaraldehyd
recent
describ
altern
sulfhydrylbas
conjug
method
improv
vivo
efficaci
multipl
murin
b
cell
lymphoma
model
pool
result
three
individu
experi
shown
fig
standard
hyb
glutaraldehyd
idklh
elicit
lowest
level
tumor
erad
fig
addit
bv
id
glutaraldehyd
idklh
gave
slightli
higher
surviv
chang
conjug
chemistri
maleimid
result
still
higher
surviv
bvand
hybderiv
id
protein
notabl
level
tumor
erad
achiev
bv
maleimid
idklh
significantli
higher
reach
standard
hyb
glutaraldehyd
idklh
vaccin
p
valu
consid
sourc
id
protein
individu
experi
bv
id
protein
conjug
show
modest
surviv
trend
favor
bv
id
hyb
id
pool
analysi
bv
id
result
greater
proport
survivor
versu
hyb
id
vs
p
valu
fig
consid
method
conjug
maleimid
conjug
result
significantli
improv
surviv
compar
glutaraldehyd
conjug
vs
p
valu
fig
result
demonstr
use
bvderiv
id
protein
maleimid
conjug
may
contribut
significantli
improv
surviv
seen
comparison
tradit
hyb
idklh
vaccin
recent
demonstr
erad
establish
lymphoma
idklh
vaccin
depend
upon
cell
mrmediat
uptak
solubl
antigen
dc
shown
provid
effici
ctl
induct
compar
abil
bv
hyb
id
protein
induc
tumorspecif
ctl
activ
glutaraldehyd
idklh
vaccin
shown
fig
ctl
activ
mice
vaccin
bv
idklh
significantli
stronger
obtain
mammalian
cellderiv
idklh
confirm
cell
vivo
effector
bv
glutaraldehyd
idklhvaccin
mice
mice
deplet
either
cell
prior
tumor
inocul
subsequ
immun
fig
vaccin
bv
glutaraldehyd
idklh
induc
signific
tumor
erad
compar
controltr
mice
hbss
vs
vaccin
control
antibodi
celldeplet
p
valu
respect
mice
receiv
control
celldeplet
antibodi
show
similar
level
surviv
fig
p
valu
indic
appar
role
cell
effector
vaccineinduc
tumor
protect
contrast
mice
deplet
cell
succumb
tumor
treat
hbss
control
thu
enhanc
ctl
induct
appear
respons
improv
efficaci
bv
idklh
vaccin
fig
sinc
antiid
antibodi
potenti
import
effector
b
cell
lymphoma
id
vaccin
nlink
glycosyl
common
variabl
region
follicular
lymphoma
ig
assess
whether
alter
glycan
structur
bv
id
would
impair
induct
antibodi
recogn
nativ
id
structur
mice
vaccin
bv
hyb
id
conjug
klh
via
glutaraldehyd
maleimid
serum
level
antibodi
bind
nativ
hyb
id
determin
elisa
use
bv
id
neither
enhanc
inhibit
humor
respons
nativ
tumor
id
fig
howev
antiid
titer
immun
maleimid
conjug
bv
hyb
id
protein
substanti
higher
seen
correspond
glutaraldehyd
conjug
notabl
highest
antibodi
level
seen
mice
vaccin
maleimideconjug
bv
idklh
base
establish
role
mannos
receptor
promot
cell
immun
protein
antigen
mannoserich
glycan
insect
cell
produc
glycoprotein
baculovirusproduc
antigen
may
offer
advantag
immunogen
vaccin
infecti
agent
tumor
inde
sever
baculovirusproduc
vaccin
recent
demonstr
efficaci
viral
infect
human
meet
challeng
produc
larg
number
id
tumor
antigen
vaccin
individu
lymphoma
patient
baculoviru
product
strategi
adopt
theoriz
product
lymphomaspecif
id
protein
insect
cell
might
yield
tumor
antigen
increas
immunogen
wish
test
hypothesi
control
set
thu
perform
sidebysid
comparison
id
protein
antigen
vaccin
produc
either
insect
mammalian
cell
interact
human
dc
vivo
potenc
murin
b
cell
lymphoma
knowledg
studi
repres
first
direct
immunolog
comparison
insect
cellderiv
versu
mammalian
cellderiv
recombin
tumor
antigen
despit
numer
recent
studi
bvproduc
protein
vaccin
varieti
infecti
agent
human
cancer
degre
recombin
tumor
antigen
secret
insect
cell
differ
immunolog
properti
mammalian
sourc
remain
incomplet
character
typic
pattern
nlink
oligomannosid
glycan
found
lymphoma
id
protein
produc
insect
cell
fig
endow
increas
bind
uptak
human
dc
fig
base
inhibit
studi
mr
appear
play
substanti
role
increas
affin
bv
id
protein
dc
although
ctype
lectinlik
scaveng
receptor
may
also
involv
also
confirm
mannoserich
antigen
prepar
addit
improv
antigen
uptak
dc
fig
contribut
dc
activ
fig
properti
add
attract
bv
vaccin
mammalian
sourc
recombin
tumor
antigen
presicc
colleagu
recent
report
klh
induc
activ
matur
human
dc
part
via
interact
mannos
receptor
light
might
conjug
klh
anoth
mannosecontain
protein
insect
cellderiv
id
offer
enhanc
dc
bind
uptak
activ
seen
mammalian
idklh
conjug
may
explain
topolog
idklh
conjug
id
protein
kd
conjug
w
w
surfac
much
larger
klh
protein
exist
multimer
complex
kd
yield
klh
cover
mani
approxim
id
molecul
thu
mannosecontain
glycan
insect
cellderiv
id
could
much
access
interact
dc
mannos
receptor
glycan
klh
carrier
protein
core
conjug
make
id
protein
mannos
content
domin
mannos
receptoridklh
interact
higher
mannos
content
protein
antigen
coupl
klh
would
import
preserv
mannos
receptor
interact
mean
increas
immunogen
vivo
found
reproduc
trend
toward
improv
tumor
erad
use
bvproduc
id
compar
produc
tumormyeloma
hybridoma
fig
vs
though
trend
reach
statist
signific
interestingli
optim
tumor
erad
studi
obtain
combin
two
rel
novel
refin
idklh
vaccin
use
insect
cellderiv
antigen
conjug
klh
via
maleimid
chemistri
therefor
would
worthwhil
test
idklh
vaccin
employ
mr
target
maleimid
conjug
clinic
trial
human
b
cell
malign
addit
provid
increas
uptak
activ
dc
bv
id
also
elicit
superior
ctl
activ
lymphoma
cell
fig
thu
therapeut
tumor
antigen
vaccin
induct
ctl
goal
insect
cell
product
recombin
protein
could
prove
advantag
given
antiid
antibodi
import
antilymphoma
effector
id
vaccin
import
exclud
possibl
alter
glycan
structur
id
produc
insect
cell
might
favor
induct
antibodi
foreign
glycan
decreas
product
recogn
nativ
id
structur
present
tumor
cell
importantli
impair
tumor
antigenspecif
antibodi
observ
bv
hyb
id
protein
elicit
similar
titer
antibodi
recogn
nativ
id
fig
thu
least
singl
case
impair
relev
tumorspecif
humor
respons
vaccin
insect
cellderiv
id
repres
concern
product
lymphomaspecif
id
protein
use
bv
insect
cell
remain
attract
approach
effici
gener
vaccin
product
quantiti
id
suffici
vaccin
obtain
near
human
follicular
lymphoma
use
technolog
usual
within
period
week
phase
ii
clinic
trial
nonhodgkin
lymphoma
sever
object
tumor
regress
observ
patient
immun
recombin
insect
cellderiv
idklh
nonetheless
phase
iii
clinic
trial
vaccin
recent
report
fail
improv
progressionfre
surviv
follicular
nonhodgkin
lymphoma
patient
immun
cytoreduct
monoclon
antibodi
therapi
second
phase
iii
vaccin
trial
follicular
nonhodgkin
lymphoma
use
recombin
mammalian
cellderiv
id
also
recent
fail
improv
progressionfre
surviv
cytoreduct
chemotherapi
third
phase
iii
trial
use
hybridomaderiv
id
protein
vaccin
follicular
lymphoma
patient
complet
remiss
chemotherapi
report
posit
result
improv
tumorfre
surviv
reason
failur
former
trial
unclear
may
relat
higher
tumor
burden
patient
time
vaccin
patient
treat
trial
use
insect
cellderiv
id
highest
tumor
burden
trial
vaccin
may
necessarili
less
potent
other
test
phase
iii
trial
current
laboratori
result
compar
singl
lymphomaspecif
id
produc
insect
cell
hybridomaderiv
id
show
modest
reproduc
immunolog
advantag
insect
cellderiv
antigen
furthermor
data
clearli
demonstr
vaccin
util
mannoserich
tumor
antigen
novel
maleimidebas
carrier
protein
conjug
method
offer
significantli
improv
vivo
antitumor
efficaci
thu
combin
new
vaccin
technolog
may
lead
improv
clinic
outcom
therapeut
cancer
vaccin
compar
carbohydr
analysi
hybridomaderiv
hyb
insect
cellderiv
bv
id
protein
oligosaccharid
cleav
purifi
protein
use
pngase
f
stain
apt
analyz
capillari
electrophoresi
alongsid
oligosaccharid
standard
elut
profil
depict
rel
fluoresc
unit
rfu
time
hybderiv
id
contain
oligosaccharid
termin
galactos
g
residu
typic
ig
insect
cellderiv
id
high
content
termin
mannos
man
residu
human
dc
mannos
receptor
allow
increas
bind
insect
cellderiv
ig
human
dc
incub
fitclabel
klh
human
iggklh
recombin
bvderiv
human
iggklh
igg
conjug
klh
via
glutaraldehyd
evalu
surfac
bind
b
murin
id
produc
bv
hyb
system
label
alexa
incub
hour
human
dc
determin
surfac
bind
ig
c
bv
idalexa
hyb
idalexa
fitcdextran
incub
human
dc
presenc
variou
inhibitor
includ
mannan
control
igg
antibodi
antimr
block
antibodi
cytochalasin
bound
antigen
quantit
flow
cytometri
bv
id
product
maleimid
conjug
result
improv
tradit
hyb
id
product
glutaraldehyd
conjug
four
day
sc
inocul
tumor
cell
group
mice
receiv
either
weekli
sc
vaccin
bvderiv
hybderiv
id
conjug
klh
via
either
maleimid
glutaraldehyd
plu
locallyadminist
gmcsf
adjuv
data
three
individu
experi
ident
endpoint
criteria
pool
tumor
erad
greatest
use
bv
id
maleimid
conjug
b
bv
hyb
idklh
group
pool
show
greater
proport
survivor
insect
cellderiv
id
protein
c
idklh
maleimid
glutaraldehyd
group
pool
show
superior
maleimideconjug
id
protein
compar
glutaraldehyd
conjug
cell
mice
vaccin
insect
cellderiv
id
requir
tumor
erad
demonstr
enhanc
effector
function
bv
glutaraldehyd
idklh
elicit
greater
ctl
activ
hyb
glutaraldehyd
idklh
mice
given
biweekli
vaccin
ctl
spleen
lymph
node
test
abil
lyse
lymphoma
cell
e
ratio
b
depend
vaccin
efficaci
cell
balbc
mice
predeplet
cell
inocul
sc
tumor
four
day
later
given
weekli
vaccin
bv
glutaraldehyd
idklh
plu
gmcsf
follow
surviv
vaccin
bv
idklh
maleimid
conjug
result
higher
tumor
antigenspecif
antibodi
titer
glutaraldehyd
conjug
group
mice
vaccin
bv
hyb
id
conjug
klh
via
either
maleimid
glutaraldehyd
weekli
week
togeth
gmcsf
mice
bled
day
later
antiid
antibodi
titer
determin
elisa
error
bar
repres
standard
deviat
among
serum
valu
individu
mice
